Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae

BMC Microbiology

Volumn 16, Issue 1, 2016, Pages

  Foerster, Sunniva ^a,b   Unemo, Magnus ^b   Hathaway, Lucy J ^a   Low, Nicola ^a   Althaus, Christian L ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Örebro University   (Sweden)

Author keywords

Antimicrobial resistance; Gonorrhoea; Neisseria gonorrhoeae; Pharmacodynamics; Time kill curves

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; PENICILLIN G; SPECTINOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; GROWTH INHIBITION; GROWTH RATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; TIME; CELL COUNT; CELL SURVIVAL; DRUG EFFECTS; GROWTH CURVE; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; THEORETICAL MODEL; TIME FACTOR;

ANTI-BACTERIAL AGENTS; CEFIXIME; CEFTRIAXONE; CELL COUNT; CELL SURVIVAL; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICINS; GROWTH CHARTS; HUMANS; IN VITRO TECHNIQUES; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; NEISSERIA GONORRHOEAE; PENICILLIN G; SPECTINOMYCIN; TETRACYCLINE; TIME FACTORS;

EID: 84988372926     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-016-0838-9     Document Type: Article

References (58)

1. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55:3538-45.
2. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273-80.
3. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858-60.
4. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587-613.
5. Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother. 2004;48:369-77.
6. Li DRC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections. Clin Pharmacokinet. 2012;37:1-16.
7. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother. 2004;48:3670-6.
8. Johnson PJT, Levin BR. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus. PLoS Genet. 2013;9:e1003123. doi: 10.1371/journal.pgen.1003123.
9. Ankomah P, Levin BR. Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012;8:e1002487. doi: 10.1371/journal.ppat.1002487.
10. Takei M, Yamaguchi Y, Fukuda H, Yasuda M, Deguchi T. Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. J Clin Microbiol. 2005;43:4321-7.
11. Jeverica S, Golparian D, Hanzelka B, Fowlie AJ, Matičič M, Unemo M. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance. J Antimicrob Chemother. 2014;69:1866-72.
12. Hamilton-Miller JM, Bruzzese T, Nonis A, Shah S. Comparative anti-gonococcal activity of S-565, a new rifamycin. Int J Antimicrob Agents. 1996;7:247-50.
13. Wade JJ, Graver MA. A fully defined, clear and protein-free liquid medium permitting dense growth of Neisseria gonorrhoeae from very low inocula. FEMS Microbiol Lett. 2007;273:35-7.
14. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009;63:1142-51.
15. Unemo M, Golparian D, Sánchez-Busó L, Grad Y, Jacobsson S, Ohnishi M, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016. [Epub ahead of print]
16. Chen CY, Nace GW, Irwin PL. A 6 × 6 drop plate method for simultaneous colony counting and MPN enumeration of Campylobacter jejuni, Listeria monocytogenes, and Escherichia coli. J Microbiol Methods. 2003;55:475-9.
17. Zwietering MH, Jongenburger I, Rombouts FM, van't Riet K. Modeling of the bacterial growth curve. Appl Environ Microbiol. 1990;56:1875-81.
18. Gagneur J, Neudecker A. cellGrowth: fitting cell population growth models. 2012. http://www.bioconductor.org/packages/release/bioc/manuals/cellGrowth/man/cellGrowth.pdf. Accessed 16 Aug 2016.
19. R Core Team. R: a language and environment for statistical computing. https://www.r-project.org/. Accessed 16 Aug 2016.
20. Ritz C, Streibig J. Bioassay analysis using R. J Stat Softw. 2005;12:1-22.
21. GitHub repository. https://github.com/sunnivas/PDfunction. Accessed 16 Aug 2016.
22. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy. 1988;8:3-33.
23. Borovinskaya MA, Pai RD, Zhang W, Schuwirth BS, Holton JM, Hirokawa G, Kaji H, Kaji A, Cate JHD. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nat Struct Mol Biol. 2007;14:727-32.
24. Borovinskaya MA, Shoji S, Holton JM, Fredrick K, Cate JHD. A steric block in translation caused by the antibiotic spectinomycin. ACS Chem Biol. 2007;2:545-52.
25. Wilson DN. The A-Z of bacterial translation inhibitors. Crit Rev Biochem Mol Biol. 2009;44:393-433.
26. Ward ME. The bactericidal action of spectinomycin on Neisseria gonorrhoeae. J Antimicrob Chemother. 1977;3:323-9.
27. Ilina EN, Malakhova MV, Bodoev IN, Oparina NY, Filimonova AV, Govorun VM. Mutation in ribosomal protein S5 leads to spectinomycin resistance in Neisseria gonorrhoeae. Front Microbiol. 2013;4:186.
28. Brown LB, Krysiak R, Kamanga G, Mapanje C, Kanyamula H, Banda B, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi. Sex Transm Dis. 2010;37:169-72.
29. Ross JDC, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect. 2012;88:6-8.
30. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect. 2012;88:589-94.
31. Hathorn E, Dhasmana D, Duley L, Ross JD. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev. 2014;3:104.
32. Williamson R, Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur J Biochem FEBS. 1985;151:475-83.
33. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol. 2004;2:289-300.
34. Comby S, Flandrois JP, Carret G, Pichat C. Mathematical modelling of growth of Escherichia coli at subinhibitory levels of chloramphenicol or tetracyclines. Res Microbiol. 1989;140:243-54.
35. Greulich P, Scott M, Evans MR, Allen RJ. Growth-dependent bacterial susceptibility to ribosome-targeting antibiotics. Mol Syst Biol. 2015;11:796.
36. Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect. 2010;86:415-21.
37. Duck PD, Dillon JR, Eidus L. Effects of thiamphenicol and chloramphenicol in inhibiting Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother. 1978;14:788-90.
38. Czock D, Keller F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn. 2007;34:727-51.
39. Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, et al. An automated fitting procedure and software for dose-response curves with multiphasic features. Sci Rep. 2015;5:14701.
40. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science. 2004;305:1622-5.
41. Dörr T, Vulić M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 2010; doi: 10.1371/journal.pbio.1000317.
42. Feng J, Kessler DA, Ben-Jacob E, Levine H. Growth feedback as a basis for persister bistability. Proc Natl Acad Sci U S A. 2014;111:544-9.
43. Maisonneuve E, Gerdes K. Molecular mechanisms underlying bacterial persisters. Cell. 2014;157:539-48.
44. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5:48-56.
45. Kint CI, Verstraeten N, Fauvart M, Michiels J. New-found fundamentals of bacterial persistence. Trends Microbiol. 2012;20:577-85.
46. Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60:699-709.
47. Conlon BP. Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells: an investigation of persister cells, their formation and their role in S. aureus disease. BioEssays. 2014;36:991-6.
48. Hayes CS, Low DA. Signals of growth regulation in bacteria. Curr Opin Microbiol. 2009;12:667-73.
49. Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, et al. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol. 2015;6:1377. http://dx.doi.org/10.3389/fmicb.2015.01377.
50. Jaffe HW, Schroeter AL, Reynolds GH, Zaidi AA, Martin JE, Thayer JD. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother. 1979;15:587-91.
51. Deguchi T, Yasuda M, Yokoi S, Ishida K-I, Ito M, Ishihara S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003;9:35-9.
52. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65:2141-8.
53. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007;45:S89-95.
54. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23:791-815.
55. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10. quiz 11-12.
56. Frimodt-Møller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents. 2002;19:333-9.
57. Dorfman MS, Wagner RS, Jamison T, Bell B, Stroman DW. The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment. Adv Ther. 2008;25:208-17.
58. Imamura Y, Higashiyama Y, Tomono K, Izumikawa K, Yanagihara K, Ohno H, et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob Agents Chemother. 2005;49:1377-80.